x

Posted 18 February, 2022

Adagio Therapeutics, Inc. appointed Mr. David Hering as new CEO

Nasdaq:ADGI appointed new Chief Executive Officer Mr. David Hering in a 8-K filed on 18 February, 2022.


  The Board intends to appoint Mr. David Hering, M.B.A. (who currently serves as the Company's Chief Operating Officer) as Interim Chief Executive Officer of the Company.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Adagio Therapeutics, Inc.
Health Care/Life Sciences • Biotechnology
Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.
Market Cap
$437M
View Company Details
Adagio Therapeutics, Inc. by TradingView
Relevant filing section
Item 5.02 
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 


(b) On February 14, 2022, Tillman Gerngross, Ph.D. communicated to the Chairperson of the Board of Directors (the "Board") of Adagio Therapeutics, Inc. (the "Company") that he agreed in principle to resign from his position as Chief Executive Officer of the Company. The Board intends to appoint Mr. David Hering, M.B.A. (who currently serves as the Company's Chief Operating Officer) as Interim Chief Executive Officer of the Company. Dr. Gerngross also agreed to transfer the duties of the Chief Executive Officer to Mr. Hering. The Company intends to provide details of the management transition in a subsequent press release and Current Report on Form 8-K.